Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.41 |
| ▸ | CDK7 | P50613 | 5/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11971273 | 0.84 | HSD17B10 (0.46) | MAPTJAK2AXLCHEK1CDK7 | |
| SCHEMBL28875476 | 0.82 | JAK2 (0.49) | JAK2CHEK1CDK7PARP1 | |
| SCHEMBL19639885 | 0.80 | JAK2 (0.42) | JAK2CHEK1CDK7PARP1 | |
| SCHEMBL2927346 | 0.79 | CTSB (0.53) | MAPTJAK2ALDH1A1MEN1KMT2A | |
| SCHEMBL29190556 | 0.76 | MAPK1 (0.54) | KDM4EMAPTJAK2AXLPDPK1 | |
| SCHEMBL2929620 | 0.76 | CDC7 (0.50) | KDM4EMAPTJAK2ALDH1A1HSD17B10 | |
| SCHEMBL2928975 | 0.76 | GRM4 (0.49) | KDM4EMAPTJAK2CHEK1ALDH1A1 | |
| SCHEMBL15687275 | 0.76 | CHEK1 (0.64) | KDM4ECHEK1CDK7ALDH1A1KMT2A | |
| SCHEMBL14338764 | 0.76 | HSD17B10 (0.52) | MAPTJAK2AXLCHEK1CDK7 | |
| SCHEMBL9909105 | 0.76 | JAK2 (0.51) | KDM4EMAPTJAK2CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1987028-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
| WO-2007095124-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | KDM4E 769/4885MAPT 1464/4885JAK2 634/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | KDM4E 769/4885MAPT 1464/4885JAK2 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.